Clinical trials: Healthy Adult Volunteers
Relative Bioavailability
To Explore the Pharmacokinetics and Relative Bioavailability of Sulfatinib Capsules in Two Different Manufacturers
This is a single-center, randomized, open, single-dose, three-cycle cross-design study, which will be only enrolled Chinese male healthy volunteers.
- Trial name
- CRC-C1721 (NCT03483259)
- Testing
- Sulfatinib T capsule, Sulfatinib R capsule
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Hutchison Medipharma Limited
Healthy Volunteer, Healthy Adult Participants
A Study to Assess the Bioequivalence of Efgartigimod PH20 SC Between Autoinjector and Prefilled Syringe in Healthy Adult Participants
The aim of this study is to compare the amount of efgartigimod in the blood over time after it is injected via Prefilled syringe (PFS) and Autoinjector (AI). The study will comprise 2 study periods of 3 weeks each.
- Trial name
- NCT07782775
- Testing
- Efgartigimod PH20 SC via PFS, Efgartigimod PH20 SC via AI
- Where
- Canada
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- argenx
Diabete Mellitus
A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fed)
This was an open-label, randomized, fed, single-dose, 2-sequence, 2- period crossover study to evaluate the pharmacokinetics and safety between single oral administration of "BR3006" and co-administration of "BR3006A", "BR3006B,"…
- Trial name
- NCT07083401
- Testing
- Dapagliflozin 10 mg/Pioglitazone 30 mg/Metformin HCl 1000 mg, Dapagliflozin 10 mg, Pioglitazone 30 mg
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Healthy Volunteers
Novel Alpha-Glucan Metabolism
These are the characteristics of the project: Monocentric: Double blind randomized and crossover: you will test all the 3 products in random order.
- Trial name
- NCT05058144
- Testing
- Drinkable solution
- Where
- Switzerland
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Influenza
A Trial of RLX-2508-102 in Healthy Volunteers
The purpose of this study is to assess safety, PK and immunogenicity profile of a single dose and multiple dose of RLX-2508 in healthy participants across different ethnic backgrounds.
- Trial name
- NCT07873671
- Testing
- RLX-2508
- Where
- 3 sites in Australia
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Atridia Pty Ltd.
Dyslipidemia
Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519
The purpose of this study is to investigate the safety/tolerability and pharmacokinetics/pharmacodynamics of CKD-519.
- Trial name
- CKD-519 FIH (NCT02156544)
- Testing
- CKD-519
- Where
- South Korea
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension and Dyslipidemia
Clinical Trial to Evaluate the Tolerability and the Pharmacokinetics of CKD-348
A phase I clinical trial to evaluate the tolerability and the pharmacokinetics of CKD-348.
- Trial name
- NCT05549401
- Testing
- CKD-348(4) F1, CKD-348(4) F2, CKD-828, D097, D337
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Postmenopausal Osteoporosis
Bioequivalence Study of SAL001 and FORSTEO in Healthy Chinese Adults
This is a single-center, randomized, open label, single-dose, the original drug controlled, crossover design, two sequence, two periods, Phase Ⅰclinical study.
- Trial name
- NCT04747392
- Testing
- SAL001, FORSTEO
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Dyslipidemia
Study to Evaluate the Safety and the Pharmacokinetics of "UI111" and "UIC202006" Under Fed Conditions
Phase 1 study to evaluate the safety and the pharmacokinetics of "UI111" and "UIC202006" in healthy adult volunteers under fed state conditions Open-label, randomized, single-dose, 2-sequence, 4-period, crossover design
- Trial name
- NCT07691268
- Testing
- Administration of UI111, Administration of UIC202006
- Where
- South Korea
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Korea United Pharm. Inc.
Cardiovascular Diseases, Obesity
New Health Devices to Improve Adherence to Physical Activity in Overweight Inactive Adults
The purpose of this study is to test in overweight and inactive adults whether the new PAI eHealh APP leads to better adherence to a physical activity regimen than the wearable step counter App from the market leader FitBit, and…
- Trial name
- NCT02774655
- Testing
- Pai APP, FitBit APP
- Where
- Norway
- Volunteers
- 60 people
- Sponsor
- Norwegian University of Science and Technology
Healthy Participants
A Study of LY03015 in Healthy Chinese and Caucasian Adult Subjects
This is an open-label, single-dose, parallel-group study to evaluate the safety, tolerability and pharmacokinetic characteristics of LY03015 in healthy Chinese and Caucasian adult subjects.
- Trial name
- NCT07671833
- Testing
- LY03015 (LPM3770164 extended-release tablets)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Normal Values of Nasal Nitric Oxide in Healthy Adults
Determination of Normal Values of Nasal Nitric Oxide in Adults
Primary ciliary dyskinesia (PCD) is a rare genetic disorder characterized by impaired airway mucociliary clearance leading to recurrent respiratory infections, bronchiectasis and eventually respiratory insufficiency.
- Trial name
- NCT02133547
- Where
- Switzerland
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Malaria
Safety, Tolerability and Antimalarial Activity of Single Doses of OZ439 and PQP
A single-centre Phase 1b study to assess the safety, tolerability, pharmacokinetic profile, and antimalarial activity of single doses of coadministered artefenomel (OZ439) and piperaquine phosphate (PQP) against early Plasmodium…
- Trial name
- NCT03542149
- Testing
- 480 mg Piperaquine phosphate, 640 mg Piperaquine phosphate, 200 mg OZ 439
- Where
- Australia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Hypertension and Dyslipidemia
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(5) 80/20/10mg
A Clinical Trial to evaluate the Pharmacokinetics and Tolerability of CKD-386(5)
- Trial name
- NCT05698043
- Testing
- CKD-386(5), D013, D326, D337
- Where
- South Korea
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Healthy Volunteers
Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion
The purpose of this study is to assess the relative potency of multiple oral doses of LUM001 and SHP626 administered for 7 days as assessed by fecal bile acid excretion in overweight and obese adult subjects.
- Trial name
- NCT02475317
- Testing
- Maralixibat, Volixibat
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Mirum Pharmaceuticals, Inc.
Focus of the Study: Safety of XFB19
A First in Human Study of the Safety, Tolerability, and the Physiologically Based Pharmacokinetics of XFB19 in Healthy Adult Volunteers.
Xfibra, Inc. is conducting a Phase 1, randomized, double-blind, placebo-controlled, first-in-human study of the safety, tolerability, and physiologically-based pharmacokinetics (PK) of single and multiple ascending doses of XFB19…
- Trial name
- NCT05361733
- Testing
- XFB19
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Xfibra, Inc.
COVID-19 (Healthy Volunteers)
Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older
The primary objectives of the study were: To describe the neutralizing antibody profile at Day 1, Day 22, and Day 36 of each study intervention group.
- Trial name
- NCT04537208
- Testing
- CoV2 preS dTM-AF03 (low-dose), CoV2 preS dTM-AF03 (high-dose), CoV2 preS dTM-AS03 (low-dose)
- Where
- 11 sites in United States
- Volunteers
- 441 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Healthy Volunteers
The Effects of Daily Supplementation of a Soluble Fiber on the Fecal Microbiota in Volunteers.
The effects of daily supplementation with NUTRIOSE® on the fecal microbiota. The study aims to evaluate the ability of NUTRIOSE® to support a beneficial modulation of the intestinal microbiota in healthy volunteers, compared with…
- Trial name
- NUTRIPOWER (NCT07846254)
- Testing
- NUTRIOSE®, Active comparator
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Roquette Freres
Clostridium Difficile Infection, Clostridium Difficile Diarrhea
Phase I Randomized, Placebo-Controlled, Double-Blind, Dose Ranging Study, Safety, Tolerability and Immunogenicity
This Phase I, randomized, placebo-controlled, double-blinded, dose ranging study to assess the safety, tolerability, and immunogenicity of 2 dose levels of C. difficile vaccine.
- Trial name
- NCT00772954
- Testing
- Vaccine diluent buffer, Clostridium difficile toxoid vaccine (50 μg), Clostridium difficile toxoid vaccine (100 μg)
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Sanofi
Healthy Volunteers (HV), Skin Irritation
Safety of Topical Exosome-Containing Liquid in Healthy Volunteers for Future Surgical Wound Use
This Phase 1 split-site pilot study will evaluate the safety and dermal tolerability of a topical exosome-containing liquid in 10 healthy adult volunteers.
- Trial name
- EV-MELSAFE (NCT07707986)
- Testing
- Exosome-Containing Liquid, Vehicle Liquid
- Where
- Kazakhstan
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- West Kazakhstan Marat Ospanov Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.